flu Antibody

Shipped with Ice Packs
In Stock

Description

Introduction to Flu Antibodies

Flu antibodies are immune proteins produced in response to influenza virus infections or vaccinations. They bind to antigenic sites on viral surface proteins—hemagglutinin (HA) and neuraminidase (NA)—to neutralize infection or mitigate disease severity. These antibodies are critical for understanding vaccine efficacy and therapeutic interventions, as demonstrated by antigenic characterization studies and clinical trials .

Types of Flu Antibodies and Their Targets

Flu antibodies can be broadly categorized by their binding regions and functional mechanisms:

Hemagglutinin (HA)-Specific Antibodies

  • HA Head Antibodies:

    • Target the HA globular head, which is highly variable and prone to antigenic drift.

    • Detected via hemagglutination inhibition (HI) assays, a correlate of protection against infection .

    • Provide strain-specific immunity but limited cross-reactivity .

  • HA Stem Antibodies:

    • Bind conserved regions of the HA stem, enabling broad neutralization across subtypes (e.g., A1, A2, B viruses).

    • Example: CR9114, a pan-influenza antibody that protects against lethal challenges in mice by disrupting viral fusion and recruiting immune effector cells via Fc-mediated functions .

Neuraminidase (NA)-Specific Antibodies

  • NA Head Antibodies:

    • Target the enzymatic active site of NA, blocking viral egress.

    • Example: 1G01, a broadly neutralizing antibody that inhibits NA activity across diverse strains, including avian and human subtypes .

  • NA "Dark Side" Antibodies:

    • Emerging targets in the NA stem region, conserved across subtypes like H3N2. These antibodies show potential for universal therapies, as demonstrated in preclinical models .

Mechanisms of Action

Flu antibodies neutralize viruses through direct and indirect mechanisms:

MechanismDescriptionKey Antibodies/Examples
NeutralizationBlocks viral attachment/entry via HA or NA inhibition.HA head antibodies (e.g., HAI titers)
Fc-Mediated EffectsRecruits immune cells (e.g., NK cells, macrophages) for antibody-dependent cytotoxicity (ADCC) or phagocytosis.CR9114 (HA stem), Flu-IVIG (Fc-functional IgG3)
Viral Egress InhibitionPrevents release of progeny viruses by blocking NA activity.NA head antibodies (e.g., 1G01)

Monoclonal Antibodies

  • CR9114:

    • Efficacy: Protects mice against A/H1N1, A/H3N2, and B/Yamagata strains via HA-stem binding and ADCC .

    • Limitation: Fails to neutralize some H2N2 and H7 strains in vitro, but retains in vivo protection .

  • 1G01:

    • Breadth: Neutralizes 12 influenza strains, including avian H5N1 and H7N9 .

    • Therapeutic Potential: Protects mice when administered 72 hours post-infection .

Antibody-Based Therapies

  • Flu-IVIG (Intravenous Immunoglobulin):

    • Influenza B: Improved outcomes in hospitalized patients by boosting Fc-functional antibodies (e.g., IgG3) .

    • Influenza A: No clinical benefit observed; higher Fc-binding antibodies correlated with worse outcomes .

  • VIR-2482:

    • Preventive Efficacy: Reduced symptomatic influenza A illness by ~57% in unvaccinated adults .

Vaccines

  • mRNA-1010:

    • Immunogenicity: Elicited higher HAI titers than standard vaccines for A/H1N1 and A/H3N2 strains, with GMFRs exceeding 4-fold rises .

    • Limitation: Suboptimal responses to B strains due to high baseline titers .

Challenges and Future Directions

  • Antigenic Drift/Shift: HA head antibodies’ limited cross-reactivity necessitates annual vaccine updates .

  • NA Antibody Dynamics: NA-specific immunity is less understood but critical for reducing transmission .

  • Therapeutic Gaps: No approved antibody therapies exist for influenza A, highlighting the need for broadly protective candidates like CR9114 or 1G01 .

Product Specs

Buffer
Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, pH 7.4
Description

The polyclonal flu antibody production involves a multi-step process. First, the recombinant Escherichia coli (strain K12) flu protein (amino acids 804-1039) is selected as the immunogen. This immunogen is administered to a rabbit through injections, repeated several times to elicit an immune response. Subsequently, the rabbit's B cells produce a significant amount of antibodies, primarily of the IgG isotype. These antibodies are then harvested from the rabbit serum and purified using protein G affinity chromatography. The flu antibody possesses the ability to react with the flu protein derived from Escherichia coli (strain K12). The purified flu antibody has been rigorously validated through ELISA and Western blot applications.

Escherichia coli flu protein (Ag43) is a phase-variable outer membrane protein playing a crucial role in the autoaggregation, flocculation, and colony morphology of E. coli K12 strains [1-4]. Ag43-mediated aggregation is macroscopically observable as cell flocculation in liquid suspensions [5]. Furthermore, Ag43 has been implicated in promoting the persistence of uropathogenic E. coli isolates within the urinary tract, underscoring its significance in bacterial virulence and pathogenesis [6]. Research has demonstrated that Ag43 facilitates specific bacterial uptake and survival within human neutrophils, highlighting its role in bacterial evasion of the host immune response [5].

References:
[1] Schembri, M., & Klemm, P. (2001). Coordinate gene regulation by fimbriae-induced signal transduction. The Embo Journal, 20(12), 3074-3081. https://doi.org/10.1093/emboj/20.12.3074
[2] Klemm, P., Hjerrild, L., Gjermansen, M., & Schembri, M. (2003). Structure‐function analysis of the self‐recognizing antigen 43 autotransporter protein from escherichia coli. Molecular Microbiology, 51(1), 283-296. https://doi.org/10.1046/j.1365-2958.2003.03833.x
[3] Krisandi, G., & Prayogo, S. (2021). Analisis potensi nanopartikel seng oksida sebagai terapi alternatif terhadap uropathogenic escherichia coli penyebab infeksi saluran kemih. Jimki Jurnal Ilmiah Mahasiswa Kedokteran Indonesia, 9(1), 38-47. https://doi.org/10.53366/jimki.v9i1.278
[4] Henderson, I., Meehan, M., & Owen, P. (1997). Antigen 43, a phase-variable bipartite outer membrane protein, determines colony morphology and autoaggregation in escherichia coli k-12. Fems Microbiology Letters, 149(1), 115-120. https://doi.org/10.1111/j.1574-6968.1997.tb10317.x
[5] Fexby, S., Bjarnsholt, T., Jensen, P., Roos, V., Høiby, N., Givskovet al. (2007). Biological trojan horse: antigen 43 provides specific bacterial uptake and survival in human neutrophils. Infection and Immunity, 75(1), 30-34. https://doi.org/10.1128/iai.01117-06
[6] Lüthje, P., & Brauner, A. (2010). Ag43 promotes persistence of uropathogenic escherichia coli isolates in the urinary tract. Journal of Clinical Microbiology, 48(6), 2316-2317. https://doi.org/10.1128/jcm.00611-10

Form
Liquid
Lead Time
Typically, we can ship your order within 1-3 business days of receiving it. Delivery times may vary depending on the purchase method or location. Please consult your local distributor for specific delivery timelines.
Synonyms
Antigen 43 (AG43) (Fluffing protein) [Cleaved into: Antigen 43 alpha chain; Antigen 43 beta chain] flu yeeQ yzzX b2000 JW1982
Target Names
flu
Uniprot No.

Target Background

Function
Ag43 is involved in regulating colony morphology variation and autoaggregation. It is suspected to function as an adhesin.
Gene References Into Functions
  1. In the K-12 leader sequence, two in-frame translation initiation codons have been identified, one upstream and the other downstream of the transcription terminator. For optimal agn43 expression, both codons need to be present. PMID: 24837285
  2. Lrp and MqsR, previously identified as agn43 regulators, do not regulate agn43 expression or ON/OFF switch frequency. PMID: 24039985
  3. The data support a model where, in an ON-phase cell, the subcellular availability of OxyR at the replication fork as it passes through the agn43 regulatory region is crucial for initiating an ON-to-OFF switch. PMID: 20118257
  4. The glycosylated form of Ag43 enhances bacterial binding to human cell lines. PMID: 16484190
  5. In vivo, the H107A substitution in sigma(32) hinders recovery from heat shock (exposure to 42 degrees C). Additionally, it leads to overexpression of the Flu protein at lower temperatures (30 degrees C), which is associated with biofilm formation. PMID: 17921304
  6. Glycosylation is likely to play significant roles in the structural and functional properties of bacterial autotransporters Ag43 at various levels. PMID: 18341480
  7. This review summarizes the proposed roles of Ag43 expression and places the studies into perspective considering the role of allelic variants, the genetic background of the bacterial strain, and the control of expression by phase variation. PMID: 18785838
  8. The authors demonstrate that Ag43 mediates bacterial adhesion in a cell line-specific manner, and structural variations in the alpha(43) domain correlate with enhanced adhesive properties to proteins of the extracellular matrix, such as collagen and laminin. PMID: 19230760

Show More

Hide All

Database Links
Subcellular Location
[Antigen 43]: Periplasm.; [Antigen 43 alpha chain]: Secreted. Cell surface. Note=The cell surface component is about 60 kDa and can be released by mild heat treatment (PubMed:22466966).; [Antigen 43 beta chain]: Cell outer membrane; Multi-pass membrane protein. Note=May form a beta-barrel.

Quick Inquiry

Personal Email Detected
Please use an institutional or corporate email address for inquiries. Personal email accounts ( such as Gmail, Yahoo, and Outlook) are not accepted. *
© Copyright 2025 TheBiotek. All Rights Reserved.